Patch.com Minuteman HS Receives Biotechnology Lab Grant Patch.com From Minuteman HS:Minuteman High School has landed another major grant from the Massachusetts Life Sciences Center to help upgrade its Biotechnology program. The $108,172 competitive grant will enable the school to outfit its Biotechnology lab with ... Read more from the original source: Minuteman HS Receives Biotechnology Lab Grant - Patch.com … Continue reading →

MPs on Tuesday clashed with biotechnology researchers over the lifting of the GMO ban. The law makers dismissed a call to have the ban lifted and called for development of home grown biotechnology solutions rather than imposing "foreign ideologies". Our researchers should focus on home grown technologies that address some of the challenges farmers are facing such as aflatoxin, drought tolerant crop varieties and the stem borer pest, said Agriculture Parliamentary committee chair Noor Mohammed. He assured local scientists that as long as they focus on need based research, the committee will lobby the government to allocate more resources. Mohammed made the remarks during a consultative meeting between the committee and biotechnology stakeholders. He noted that there has not been any scientific evidence on the safety of GMOs, or any guarantee that it can offer a solution to food insecurity in the country. Read: University students want government to issue licence of GMO maize Also read: State launches GMO labelling mark amid jitters of effect on existent ban There is no research in the world specifically stating on the safety of the technology. Let any scientist give evidence in Kenya own up and that GMO is safe for human consumption, … Continue reading →

With five U.S. patents issued and dozens more filed and pending around the world, On Target Laboratories LLC is working to advance its revolutionary fluorescent imaging technology that could help surgeons pinpoint and remove more cancerous tissues than has ever been possible while preserving more healthy tissue for patients. Headquartered at Purdue Research Park of West Lafayette, the company is developing a series of molecules, which, when administered intravenously, show promise in targeting many types of cancer cells, said Dr. Sumith Kularatne, On Targets vice president of research and development. In addition to our current U.S. patents, we have 11 more either filed or pending in the U.S., Kularatne said. We have another 33 patents pending worldwide. These patents are very important in helping us move our discoveries to the public where they can help people. These molecules carry a fluorescent dye and target diseased cells, including cancer, enabling surgeons to better diagnose and remove the disease while avoiding collateral damage to healthy tissue such as nerves. OTL38 is a novel compound consisting of a folic acid-targeting molecule, or ligand, linked to a near-infrared dye. Following current clinical trial protocols, OTL38 is injected two hours before surgery and is intended … Continue reading →

Cellect Biotechnology Ltd. (NASDAQ: APOP) Cellect Biotechnology is having an incredibly strong day in the market today. As soon as the session opened, the stock was already trading on overwhelmingly impressive gains. From there, we've seen a continuation of strong movement. Below, we'll talk about what we're seeing from the stock, why, and what we'll be watching for with regard to APOP ahead. As mentioned above, Cellect Biotechnology is having an incredibly strong day in the market today. At the opening bell, the stock was already trading well into the green. Throughout the morning, we've seen a continuation of gains. At the moment (10:52), APOP is trading at $6.91 per share after a gain of $1.08 per share (18.52%) thus far today. As is almost always the case, our partners at Trade Ideas were the first to send the alert that APOP was making a run for the top. As soon as we received the alert, the CNA Finance team started digging to see exactly what was causing the movement. It didn't take long to uncover the story. The gains are ultimately the result of a positive data release. Early this morning, Cellect Biotechnology released positive results from its clinical … Continue reading →

Market Summary Follow Puma Biotechnology Inc is a A biopharmaceutical company PBYI - Market Data & News PBYI - Stock Valuation Report Puma Biotechnology Inc (PBYI) traded on unusually high volume on Feb. 21, as the stock lost 4.72% to close at $38.35. On the day, Puma Biotechnology Inc saw 1.1 million shares trade hands on 8,009 trades. Considering that the stock averages only a daily volume of 715,433 shares a day over the last month, this represents a pretty significant bump in volume over the norm. Generally speaking, when a stock experiences a sudden spike in trading volume, it may be seen as a bullish signal for investors. An increase in volume means more market awareness for the company, potentially setting up a more meaningful move in stock price. The added volume also provides a level of support and stability for price advances. The stock has traded between $73.27 and $19.74 over the last 52-weeks, its 50-day SMA is now $34.44, and its 200-day SMA $41.65. Puma Biotechnology Inc has a P/B ratio of 15.46. Puma Biotechnology Inc is a biopharmaceutical company. It is engaged in the acquisition, development and commercialization of products to enhance cancer care. Headquartered in … Continue reading →